Piyasa Haberleri

En güncel finans ve ekonomi haberlerini, piyasa gelişmelerini, raporları ve analizleri PipVero’da takip edin.

Kaynak: Proactive Investors Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Genel rejects £202 million cash approach from DNO

Genel rejects £202 million cash approach from DNO

Genel Energy PLC (LSE:GENL, FRA:4VL, OTC:GEGYY) has rejected a £202 million cash approach from DNO, its Norwegian rival in the Kurdistan region of Iraq. DNO has taken the proposal public after being rebuffed, a move that raises pressure on the Genel board to open talks.

İlgili Semboller 1
GEGYY GEGYY
Kaynak: Proactive Investors
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Proactive Investors Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, has cut its revenue guidance for 2026 after clients deferred orders and a US site took longer than expected to come online. The company now expects full-year revenues of £180 million to £200 million.

İlgili Semboller 1
OXB OXB
Kaynak: Proactive Investors
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Reuters Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Israel's Ratio Petroleum sweetens Pharos Energy offer, outbidding Serica

Israel's Ratio Petroleum sweetens Pharos Energy offer, outbidding Serica

Israel-based Ratio Petroleum Energy raised its takeover bid for Pharos Energy to about £146.4 ​million ($196.97 million) on Friday, outbidding rival oil ‌producer Serica Energy and winning back the board's recommendation.

İlgili Semboller 1
SOCLF SOCLF
Kaynak: Reuters
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Ocugen Q2 Earnings Call Highlights

Ocugen Q2 Earnings Call Highlights

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.

İlgili Semboller 1
OCGN OCGN
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Nova Q2 Earnings Call Highlights

Nova Q2 Earnings Call Highlights

Nova NASDAQ: NVMI reported record second-quarter revenue of $255 million, up 8% sequentially and 16% from a year earlier, as demand increased across its semiconductor process-control portfolio. The company said revenue reached the high end of its guidance range, while non-GAAP diluted earnings per share of $2.51 exceeded the high end of its outlook.

İlgili Semboller 1
NVMI NVMI
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Novavax Q2 Earnings Call Highlights

Novavax Q2 Earnings Call Highlights

Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.

İlgili Semboller 1
NVAX NVAX
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Natera Q2 Earnings Call Highlights

Natera Q2 Earnings Call Highlights

Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.

İlgili Semboller 1
NTRA NTRA
Kaynak: MarketBeat
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

İlgili Semboller 1
NTLA NTLA
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
NETGEAR Q2 Earnings Call Highlights

NETGEAR Q2 Earnings Call Highlights

NETGEAR NASDAQ: NTGR reported second-quarter 2026 revenue of $168.6 million, down 1.2% from a year earlier but up 6.1% sequentially, as growth in its enterprise segment offset continued pressure in consumer products. The company said revenue and non-GAAP operating margin exceeded the high end of its guidance range.

İlgili Semboller 1
NTGR NTGR
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
NetScout Systems Q1 Earnings Call Highlights

NetScout Systems Q1 Earnings Call Highlights

NetScout Systems NASDAQ: NTCT reported first-quarter fiscal 2027 revenue growth of 13%, citing demand for its service assurance offerings, government-related orders and contributions from its recently acquired cloud DDoS business. The company reaffirmed its full-year outlook, while cautioning that some government orders arrived earlier than anticipated and are expected to affect second-quarter comparisons.

İlgili Semboller 1
NTCT NTCT
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: MarketBeat Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Insight Enterprises Q2 Earnings Call Highlights

Insight Enterprises Q2 Earnings Call Highlights

Insight Enterprises NASDAQ: NSIT reported second-quarter results that exceeded its expectations, with broad-based growth in hardware, cloud and services helping drive operating leverage. The company raised its full-year outlook for gross profit growth and adjusted diluted earnings per share while outlining a three-year “One Insight Plan” centered on AI infrastructure, AI services, operational efficiency and talent development.

İlgili Semboller 1
NSIT NSIT
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap